Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00010

Target Information
NameDopamine receptor    
Type of targetSuccessful target    
[ICD9: 458, 796.3   ICD10: I95]
Nausea and vomiting
[ICD9: 787, 787.0   ICD10: R11]
Neuroleptic malignant syndrome[3]
Neurotensin-like immunoreactivity[4]
[ICD9: 295   ICD10: F20]
Drug(s)Bromocryptine mesylateApprovedParkinson's Disease[6]
DomperidoneApprovedGastrointestinal problems[10][11]
FencamfamineApprovedDepressive fatigue in convalescence[12]
Ibopamine hciApprovedCardiotonic[7][13]
LevodopaApprovedParkinson's disease[14]
LisurideApprovedParkinson's disease[15][16][17]
Prolixin decanoateApprovedChronic schizophrenics[18][4]
Ropinirole HClApprovedParkinson's Disease[6]
ThiethylperazineApprovedNausea and vomiting[19][3]
SLV-308Phase III completedParkinsoní»s disease[21]
DU-127090Phase IIIParkinsoní»s Disease[6]
Entacapone+levodopa+carbidopaPhase IIIParkinsoní»s disease; Restless legs syndrome[22]
BL-1020Phase II completedSchizophrenia[23]
BIM23A760Phase IIAcromegaly[24]
BioChemical ClassG-protein coupled receptor (rhodopsin family)    
PathwayCalcium signaling pathway
Gap junction
Neuroactive ligand-receptor interaction
Related US Patent6,316,027
Target ValidationClick to Find Target Validation Information.    
AgonistBromocryptine mesylate[6]
Ropinirole HCl[6]
Prolixin decanoate[18][4]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Dopamine and migraine. Neurology. 1997 Sep;49(3):650-6. To Reference
Ref 2Tardive dyskinesia as a result of long-term prochlorperazine use. South Med J. 1996 Oct;89(10):989-91. To Reference
Ref 3Torecan-induced neuroleptic malignant syndrome. Harefuah. 1990 May 15;118(10):576-8. To Reference
Ref 4The effects of chronic neuroleptic treatment on neurotensin-like immunoreactivity in the rat central nervous system. Brain Res. 1985 Jun 3;335(2):334-6. To Reference
Ref 5The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs? Psychol Med. 1977 May;7(2):213-21. To Reference
Ref 6Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference
Ref 7Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 8ARMC 30 To Reference
Ref 9298 To Reference
Ref 10Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. Epub 2005 Jul 22. To Reference
Ref 11The significance of disordered gastric emptying. Z Gastroenterol. 1986 Sep;24 Suppl 2:45-54. To Reference
Ref 12Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31. To Reference
Ref 133063492 To Reference
Ref 14Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications. J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):156-62. Epub 2009 Apr 28. To Reference
Ref 15Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. To Reference
Ref 16Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. To Reference
Ref 17Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology. 1985 Mar;24(3):199-206. To Reference
Ref 18The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain. Psychopharmacology (Berl). 2008 Jan;195(4):559-68. Epub 2007 Sep 23. To Reference
Ref 19Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3. To Reference
Ref 20Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. To Reference
Ref 21Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 22Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. To Reference
Ref 23The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. To Reference
Ref 24Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93. To Reference
Ref 25Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543